Category
Biologics & Advanced Therapies
Modern targeted treatments for moderate-severe IBD
Tysabri vs Tremfya for Crohn's Disease: Key Differences
Tysabri and Tremfya represent very different positions in the Crohn's biologic landscape. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for Crohn's in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs tremfya crohn's comparison.
Tysabri vs Stelara for Crohn's Disease: How They Compare
Tysabri and Stelara take very different mechanistic approaches to moderate-to-severe Crohn's disease. Stelara (ustekinumab) is an IL-12/23 biologic that is widely prescribed for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. Both drugs are often considered in patients with complex treatment histories who have failed anti-TNFs or other options. This guide walks through the tysabri vs stelara crohn's comparison.
Tysabri vs Skyrizi for Crohn's Disease: Which to Choose?
Tysabri and Skyrizi represent two different generations and positions in the Crohn's biologic landscape. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on ADVANCE, MOTIVATE, and FORTIFY, increasingly prescribed as a first-line or second-line option. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs skyrizi crohn's comparison.
Tysabri vs Remicade for Crohn's Disease: Key Differences
Tysabri and Remicade are two IV biologics for moderate-to-severe Crohn's disease that take very different mechanistic approaches and differ sharply in how they are prescribed, monitored, and accessed. Remicade (infliximab) is a widely prescribed first-line IV anti-TNF biologic. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs remicade crohn's comparison.
Tysabri vs Omvoh for Crohn's Disease: A Comparison
Tysabri and Omvoh represent very different positions in the Crohn's biologic landscape. Omvoh (mirikizumab) is the newest IL-23 p19-selective biologic for Crohn's, approved in January 2025 based on VIVID-1. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs omvoh crohn's comparison.
Tysabri vs Humira for Crohn's Disease: A Comparison
Tysabri and Humira take very different mechanistic approaches to moderate-to-severe Crohn's disease, and they differ sharply in how they are prescribed, monitored, and accessed. Humira (adalimumab) is a subcutaneous anti-TNF biologic that is widely prescribed as a first-line biologic for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs humira crohn's comparison.
Tysabri vs Entyvio for Crohn's: Comparing Integrin Biologics
Tysabri and Entyvio both target integrins in the pathway that drives immune cell trafficking in Crohn's disease, but they differ in which integrin subunit they block, and that difference creates profoundly different safety profiles. Entyvio (vedolizumab) is gut-selective and has a favorable safety record. Tysabri (natalizumab) blocks a broader integrin target that includes trafficking to the brain, creating a risk of progressive multifocal leukoencephalopathy (PML) that requires the TOUCH program to manage. This guide walks through the tysabri vs entyvio crohn's comparison.
Tysabri vs Cimzia for Crohn's Disease: A Patient Guide
Tysabri and Cimzia are both less commonly prescribed biologics for moderate-to-severe Crohn's disease, each with specific niches in the treatment landscape. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic with a distinctive structure that makes it notable for pregnancy considerations. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. This guide walks through the tysabri vs cimzia crohn's comparison.
Tremfya vs Stelara for Ulcerative Colitis: Key Comparison
Tremfya and Stelara are two Johnson & Johnson IL-23 pathway biologics for moderate-to-severe ulcerative colitis. Stelara has been the established UC option since its UNIFI-based approval, while Tremfya received UC approval in 2024 based on the QUASAR and ASTRO trials. The drugs differ in mechanism. Tremfya selectively blocks IL-23 through p19, while Stelara blocks both IL-12 and IL-23 through p40. For Crohn's, GALAXI 2 and 3 demonstrated Tremfya's superiority over Stelara on endoscopic endpoints. UC patients often ask whether similar logic applies to their disease. This guide walks through the tremfya vs stelara ulcerative colitis decision.
Tremfya vs Stelara for Crohn's Disease: GALAXI Trial
Tremfya and Stelara are both Johnson & Johnson biologics for moderate-to-severe Crohn's disease, and they present a rare scenario where a manufacturer's newer drug is being compared head-to-head with its predecessor. Stelara has been the workhorse IL-12/23 biologic in IBD since its Crohn's approval in 2016. Tremfya is a newer p19-selective IL-23 biologic that J&J brought to IBD markets starting in 2024. The GALAXI 2 and GALAXI 3 trials directly compared these two drugs in Crohn's, and the results favor Tremfya on endoscopic endpoints. This guide walks through what Crohn's patients need to know when weighing the tremfya vs stelara crohn's decision.
Tremfya vs Remicade for Ulcerative Colitis: Patient Guide
Tremfya and Remicade take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Remicade is the original anti-TNF for UC, with an efficacy record stretching back to ACT-1 and ACT-2 in the mid-2000s. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, offering both IV and fully subcutaneous induction pathways. UC patients commonly weigh these two drugs when choosing a first biologic or switching after loss of response. This guide walks through the tremfya vs remicade ulcerative colitis decision.
Tremfya vs Remicade for Crohn's: Comparing Biologics
Tremfya and Remicade are two of the biologics Crohn's patients commonly consider when Remicade has lost effect or when starting a first biologic. Remicade has been the anti-TNF standard for more than two decades. Tremfya is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2024 based on the GALAXI trial program. The drugs take very different mechanistic approaches and offer different administration options, which shapes the decision for many Crohn's patients. This guide walks through the tremfya vs remicade crohn's comparison.